SchwartzbergLS, YeeLK, SenecalFM. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist2004;9:696–707.
2.
GlaspyJ, BergR, TomitaD, RossiG, Vadhan-RajS.Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 μg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA) (abstract 8125). Presented at: American Society of Clinical Oncology Annual Meeting, Orlando, FL, May 14–17, 2005.
3.
WaltzmanR, CrootC, JusticeGR, FesenM, CharuV, WilliamsD.Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist2005;10:642–50.
4.
LefebvreP, GosselinA, FastenauJ.Treatment patterns and frequency of outpatient visits in adults with cancer receiving erythropoietic agents in a managed care organization (abstract). J Manag Care Pharm2005;11:284.
